2024 KSoLA consensus on secondary dyslipidemia - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39252486/
Elevated blood cholesterol and triglyceride levels induced by secondary causes are frequently observed. The identification and appropriate handling of these causes are essential for secondary dyslipidemia treatment. Major secondary causes...
Secondary dyslipidemia necessitates identifying and addressing underlying causes before initiating lipid-lowering therapy, focusing on dietary factors, metabolic diseases, and medication side effects.
Share
Practical solutions for implementation of blood cholesterol guidelines in clinical practice - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37634754/
Underutilization of lipid-lowering therapy (LLT) and failure to attain guideline-recommended low-density lipoprotein cholesterol (LDL-C) goals are important quality gaps in cardiovascular risk optimization, especially among patients with atherosclerotic cardiovascular disease...
Many patients with atherosclerotic cardiovascular disease (ASCVD) do not achieve recommended LDL-C levels due to underutilization of lipid-lowering therapy; multifaceted interventions are needed for optimal management.
Share
Insights into the interplay between gut microbiota and lipid metabolism in the obesity management of canines and felines - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39118186/
Obesity is a prevalent chronic disease that has significant negative impacts on humans and our companion animals, including dogs and cats. Obesity occurs with multiple comorbidities, such as diabetes, hypertension,...
The review explores lipid metabolism's role in obesity-related disorders in dogs and cats, emphasizing gut microbiota and management strategies including nutritional interventions for effective obesity treatment.
Share
Medications for Lipid Control: Statins vs Newer Drugs - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/39111897/
In the primary and secondary prevention of atherosclerotic cardiovascular disease (ASCVD), statins are the primary pharmacologic intervention for ASCVD risk reduction. Statins have proven efficacy and safety in reducing cardiovascular...
Statins are key for ASCVD prevention, with proven efficacy. Alternative therapies like ezetimibe and PCSK9 inhibitors, along with emerging treatments, enhance lipid management and cardiovascular outcomes.
Share
PCSK9 inhibition: from effectiveness to cost-effectiveness
Source : https://pubmed.ncbi.nlm.nih.gov/38988669/
Dyslipidaemia is a complex disorder characterised by abnormal lipid levels in the blood, including cholesterol and triglycerides, and plays an important role in the development of atherosclerotic cardiovascular disease. Most...
PCSK9 inhibitors are effective in lowering LDL cholesterol and offer significant benefits for high-risk patients. Despite high costs and mixed cost-effectiveness results, they remain a valuable treatment option.
Share